Xenografts from trametinib-treated mice displayed increased ALDH1 levels assessed via immunohistochemical staining in comparison to samples obtained from control group (Figure S13), suggesting that trametinib treatment caused CSC enrichment in tumor tissue. This evidence concerns the gene ALDH1A1 and neoplasm.